Intuitive Surgical ISRG remains a procedure-driven growth story built around robotic systems, instruments, services and software.
The central question for investors is whether da Vinci 5, SP, Ion and digital tools can keep expanding clinical reach while offsetting weaker areas such as bariatric surgery, U.S. deferrable procedures and China placements.
ISRG Builds on a Broad Robotic Platform
Intuitive Surgical’s platform spans da Vinci multi-port systems, the da Vinci SP single-port platform and Ion. Da Vinci supports robot-assisted soft tissue surgery across general surgery, urology, gynecology, cardiothoracic care and head and neck specialties.
Ion extends the company into minimally invasive lung biopsy through a flexible, robotic-assisted, catheter-based platform. ISRG is building a broader care ecosystem designed to widen procedure reach across specialties and settings.
Intuitive Surgical Gains From Recurring Revenue
Recurring revenue is central to the model because instruments, accessories, leases and services rise with utilization and installed-base growth. In the second quarter of 2026, recurring revenue increased 19% to $2.47 billion.
That represented 85% of total revenue, making the business less dependent on one-time system sales. Instruments and accessories revenues rose 18% to $1.73 billion, while service revenues grew 21% to $472 million.
Intuitive Surgical, Inc. Price and Consensus
Intuitive Surgical, Inc. price-consensus-chart | Intuitive Surgical, Inc. Quote
ISRG Procedure Growth Still Drives the Story
Procedure volume remains the key operating indicator. In the second quarter of 2026, total da Vinci and Ion procedures increased 16% year over year, including 15% da Vinci growth and 36% Ion growth.
International da Vinci procedures rose 20%, with Europe and Asia each up 20%. SP procedures increased 61%, while cardiac and nipple-sparing mastectomy procedures rose 39% and 43%, respectively. Management maintained its 2026 da Vinci procedure growth outlook of 13.5% to 15.5%, with expectations near the midpoint.
Intuitive Surgical Expands the Ecosystem With Digital Tools
Software and data are becoming more important to the Intuitive Surgical’s business model. The company began rolling out more than 100 planned da Vinci 5 updates focused on telepresence, simulation-based training and care-team workflow.
It also completed its first My Intuitive+ renewals, covering telepresence, simulation and artificial intelligence-driven case insights. No customer in the initial cohort opted out, suggesting these tools can deepen engagement and make the installed base more valuable.
What ISRG Investors Should Watch Next
The bottom line is that ISRG still has a clear platform-dependent growth scenario. Da Vinci 5 upgrades, Ion adoption, SP growth, recurring revenue and digital tools all support a wider ecosystem.
Risks remain visible. U.S. da Vinci procedure growth moderated to 12% in the second quarter from 14% in the first quarter, bariatric procedures declined at a high-single-digit rate and China remains pressured by lower tender activity, local competition and policy-driven pricing.
Medtronic plc MDT and Johnson & Johnson JNJ are relevant comparables for investors tracking surgical robotics and digitally enabled medical technology. Their presence keeps the competitive context important, even as ISRG maintains a competitive moat with high installed systems, improving utilization and procedure-linked revenue as well as strong clinical evidence.
Investors should pair this operating view with ISRG’s current Zacks Rank #2 (Buy) and Zacks Style Scores of B before forming a fuller stock view. The Zacks Rank is a short-term timeliness indicator, while the Style Scores help evaluate value, growth and momentum characteristics. Higher grades, especially A or B, are more favorable when considered alongside top-ranked stocks, but they should be weighed with procedure trends, placement dynamics and margin risks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).